India Cracks Down on Unregulated Use of Cheap Generic Weight-Loss Drugs Amid Health Risk Warnings
Summary
India has tightened regulations on cheap generic weight-loss drugs amid warnings about health risks from unregulated use, following the patent expiry of semaglutide.
Key Points
- India's Ministry of Health has issued warnings over misuse of cheap generic weight-loss drugs.
- Generic semaglutide drugs, like those similar to Ozempic and Wegovy, are rapidly entering the Indian market after patent expiry.
- Health authorities warn about serious side effects from unsupervised use of these drugs.
- India's drug regulators are banning misleading promotion and tightening inspections to control usage.
